Abstract:Background Accurate differentiation between lung adenocarcinoma (AC) and lung squamous cell carcinoma (SCC) is crucial owing to their distinct therapeutic approaches. MicroRNAs (miRNAs) exhibit variable expression across subtypes, making them promising biomarkers for discrimination. This study aimed to identify miRNAs with robust discriminatory potential between AC and SCC and elucidate their clinical significance. Methods MiRNA expression profiles for AC and SCC patients were obtained from The Cancer Genome Atlas (TCGA) database. Differential expression analysis and supervised machine learning methods (Support Vector Machine, Decision trees and Naïve Bayes) were employed. Clinical significance was assessed through receiver operating characteristic (ROC) curve analysis, survival analysis, and correlation with clinicopathological features. Validation was conducted using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Furthermore, signaling pathway and gene ontology enrichment analyses were conducted to unveil biological functions. Results Five miRNAs (miR-205-3p, miR-205-5p, miR-944, miR-375 and miR-326) emerged as potential discriminative markers. The combination of miR-944 and miR-326 yielded an impressive area under the curve of 0.985. RT-qPCR validation confirmed their biomarker potential. miR-326 and miR-375 were identified as prognostic factors in AC, while miR-326 and miR-944 correlated significantly with survival outcomes in SCC. Additionally, exploration of signaling pathways implicated their involvement in key pathways including PI3K-Akt, MAPK, FoxO, and Ras. Conclusion This study enhances our understanding of miRNAs as discriminative markers between AC and SCC, shedding light on their role as prognostic indicators and their association with clinicopathological characteristics. Moreover, it highlights their potential involvement in signaling pathways crucial in non-small cell lung cancer pathogenesis.

Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review

Research Progress on Lung Cancer Related MicroRNAs

MiRNA-based therapeutic strategy in lung cancer.

Advances of Microrna in Lung Cancer

MicroRNA-targeted therapeutics for lung cancer treatment

MicroRNAs modulation in lung cancer: exploring dual mechanisms and clinical prospects

Roles of Microrna in Diagnosis, Therapy and Prognosis of Lung Cancer

A comprehensive in silico analysis and experimental validation of miRNAs capable of discriminating between lung adenocarcinoma and squamous cell carcinoma

Research progress on the relationship between lung cancer drug-resistance and microRNAs

MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?

Unraveling Therapeutic Opportunities and the Diagnostic Potential of microRNAs for Human Lung Cancer

MicroRNAs in non‐small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential

miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential

MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer

Advances of Microrna in Diagnosis and Treatment of Lung Cancer

Comparison of oncolytic virotherapy and nanotherapy as two new miRNA delivery approaches in lung cancer

Involvement of Micrornas in Lung Cancer Biology and Therapy

MicroRNAs in Laryngeal Cancer: Implications for Diagnosis, Prognosis and Therapy.

MicroRNAs in metabolism for precision treatment of lung cancer

In-depth Bioinformatic Analysis of Lung Cancer-Associated Microrna Targets

The Potential Clinical Applications and Prospects of Micrornas in Lung Cancer.